GRI stock forecast, quote, news & analysis

Key Takeaways

• GRI Bio (GRI) shares rose approximately 11.9% over the trailing 30 days, from a closing price of $1.68 on October 8, 2026 to $1.88 on November 6, 2026.
• The advance was punctuated by a sharp single-session gain of roughly 21.3% on November 6, reflecting the high volatility typical of clinical-stage micro-cap biotech names.
• H.C. Wainwright reiterated a Buy rating and a $10 price target in mid-October, pointing to Bristol Myers Squibb's Phase 3 IPF data as validating the idiopathic pulmonary fibrosis category.
• The lead candidate, GRI-0621, an oral therapy for idiopathic pulmonary fibrosis, remains the central value driver following positive Phase 2a data reported in early September.
• Broader analyst consensus is a Strong Buy with an average 12-month price target of $18.50, though estimates vary widely given the stock's small size and thin liquidity.
• As a pre-revenue biotechnology company, GRI's share price is driven primarily by clinical readouts, financing events, and analyst sentiment rather than fundamentals tied to revenue or earnings.
• For additional detail, investors can review GRI Bio's Price Targets, Earnings, and Forecast pages.
• Explore Trending AI Robots to see curated AI trading strategies across thousands of tickers.

GRI Bio (GRI) Company Overview and Market Position

GRI Bio, Inc. is a La Jolla, California-based clinical-stage biopharmaceutical company focused on developing immune cell modulators for the treatment of inflammatory, fibrotic, and autoimmune diseases. Its platform targets Natural Killer T (NKT) cells, which act earlier in the inflammatory cascade, with the goal of interrupting disease progression and restoring the immune system to homeostasis.

The company's lead program, GRI-0621, is an oral RARβγ agonist and type 1 invariant NKT cell inhibitor being developed for idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease with significant unmet need. A second candidate, GRI-0803, is a type 2 NKT cell agonist advancing through IND-enabling studies for autoimmune indications such as systemic lupus erythematosus and multiple sclerosis. The company also maintains a proprietary library of more than 500 compounds. Investors follow GRI primarily for the clinical trajectory of GRI-0621 and the company's ability to secure additional capital.

GRI Bio (GRI) Stock Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, GRI shares moved from a closing price of $1.68 on October 8, 2026 to $1.88 on November 6, 2026, a gain of approximately 11.9%. The period was uneven: the stock declined through mid-October to the low $1.30s before recovering through late October and early November, culminating in a roughly 21.3% single-session surge on November 6.

Over the trailing quarter, the picture is one of pronounced volatility. The stock traded near $1.47 in early August, climbed to an intraday high around $3.36 in early September, pulled back into the mid-$1.30s by mid-October, and subsequently recovered toward $1.88. This multi-month swing reflects the outsized price action characteristic of a low-float clinical-stage biotech company whose shares are sensitive to data catalysts and shifts in sentiment.

What Drove GRI Stock Price in the Last 30 Days

The recent advance was supported by renewed analyst attention. In mid-October, H.C. Wainwright reiterated a Buy rating and a $10 price target on GRI Bio, citing data from Bristol Myers Squibb's Phase 3 ALOFT-IPF trial of admilparant as validating the broader IPF opportunity. The firm's commentary framed GRI-0621's differentiated mechanism within a category gaining clinical momentum.

Separately, GRI Bio held its 2026 Annual Meeting of Stockholders on November 4, at which shareholders elected two directors, ratified the company's auditor, and approved an expansion of the equity incentive plan. While governance-related, such events can influence sentiment for a thinly traded name. It is worth noting that the sharp November 6 advance was not accompanied by a company-specific announcement, and outsized daily moves in micro-cap biotech often occur on thin trading volumes. A counterpoint to the bullish view came from Weiss Ratings, which reiterated a Sell (E+) rating in mid-October.

What Drove GRI Stock Performance Over the Last Quarter

The broader quarterly trend has been shaped by clinical progress in the company's lead program. In early September, GRI Bio reported positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis, showing a favorable placebo-adjusted change in forced vital capacity and no serious treatment-emergent adverse events in the treated arm. This followed U.S. Food and Drug Administration Orphan Drug Designation granted in June 2026 and additional translational biomarker data reinforcing the therapy's mechanism.

Alongside clinical momentum, financing activity has been a recurring theme. The company reported cash of approximately $10.9 million at June 30, 2026 and has stated that existing resources are expected to fund operations into 2027, while also disclosing substantial doubt about its ability to continue as a going concern without additional capital. This combination of clinical validation and persistent financing risk helps explain the stock's wide trading range over the quarter.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a platform that offers hundreds of automated strategies trading thousands of tickers. Only the top-performing and most relevant bots are featured in this section, giving users a focused view of strategies currently demonstrating strength. The bots span a range of approaches, timeframes, and performance metrics, allowing traders to compare strategies aligned with their own objectives and risk tolerance. For those interested in systematic, data-driven approaches to the market, the page offers a practical starting point for exploring automated trading tools.

GRI Stock Forecast Drivers: What Investors Should Watch Next

Several factors are likely to shape GRI Bio's share price going forward. The company's third-quarter 2026 earnings report is expected in mid-November, with analysts anticipating a narrower loss than in the prior-year period; updates on cash runway, operating expenses, and any additional financing plans will be closely watched. Progress on GRI-0621, including next steps toward a registration-enabling development path, and the advancement of GRI-0803 through IND-enabling studies represent key clinical catalysts.

Investors should also monitor analyst price-target revisions, broader sector sentiment around IPF treatments, and any developments related to Nasdaq listing requirements and future capital raises, which carry dilution risk. As with all early-stage biotechnology companies, clinical trial outcomes, regulatory decisions, and financing conditions will ultimately determine the stock's trajectory, and these carry substantial inherent risk.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations